The shadow of generic competition has repeatedly loomed above copyright’s famous drug, Viagra, sparking questions about the future of related pharmaceutical holdings. While first times saw substantial returns, the exclusivity lapse has created the door for discounted substitutes, possibly reducing revenue and creating a genuine risk for sharehold